# Mecapegfilgrastim

Source: https://onco.cc/drugs/mecapegfilgrastim/  
OnCo record `mecapegfilgrastim` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia.

## Summary

Mecapegfilgrastim (Aiduo) is a long-acting pegylated G-CSF developed by Jiangsu Hengrui. The NMPA approved it in May 2018 to reduce the incidence and duration of neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid cancers. It is one of the most widely used supportive-care biologics in China.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Aiduo; 19K
- Tags: china; nmpa-approved
- Code: HHPG-19K
- Modality: Long-acting granulocyte colony-stimulating factor (growth factor support)
- Mechanism: A pegylated form of G-CSF that tells the bone marrow to make neutrophils, shortening the low-neutrophil period after chemotherapy.
- Approvals: CN 2018: Prevention of chemotherapy-induced neutropenia in non-myeloid cancers

## Sources

- ClinicalTrials.gov: trials of mecapegfilgrastim: https://clinicaltrials.gov/search?intr=mecapegfilgrastim

## Connected records

- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/mecapegfilgrastim.json